N-(2-aminoethyl)homopiperazine | 63872-67-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂卓
• 英文名称: N-(2-aminoethyl)homopiperazine
• 英文别名: 2-(1,4-Diazepan-1-yl)ethan-1-amine；2-(1,4-diazepan-1-yl)ethanamine
• CAS: 63872-67-3
• 化学式: C₇H₁₇N₃
• 分子量: 143.232
• InChiKey: BPWDBFGTCPZSQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-(1,4-diazepan-1-yl)acetonitrile 生成 N-(2-aminoethyl)homopiperazine
  参考文献：
  名称：

  Substituted azetidiones as anti-inflammatory and antidegenerative agents

  摘要：

  本文披露了用于治疗多种弹性蛋白酶介导疾病的替代氮杂环丙酮。

  公开号：

  US05747485A1

文献信息

• PYRAZOLE DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1762568A1

  公开（公告）日：2007-03-14

  A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

  由式(I)表示的化合物： （其中Ar1代表可能具有1到3个取代基的苯基，或者是非取代的5-或6-成员芳香杂环基团；Ar2代表（i）非取代的苯基团，（ii）已被1到3个来自羰胺基、氨基、羟基、低烷氧基和卤原子的群或原子取代的较低烷基基团取代的苯基团，或者（iii）已被1到3个来自低烷基基团、低炔基基团、低烷酰基团、羰胺基、氰基、氨基、羟基、低烷氧基和卤原子的群或原子取代的5-或6-成员含氮芳香杂环基团；X代表由式(II)表示的基团： （其中环结构表示可能具有除了式(II)中显示的氮原子之外，从氮、氧和硫中选择的一个杂原子的4-到7-成员杂环基团，并且可能被1到4个来自低烷基基团、羰胺基、氨基、羟基、低烷氧基、氧基、低烷酰基团、低烷基磺酰基团和卤原子的群或原子取代）），其盐，该化合物或其盐的溶剂化合物，以及药物。
• [EN] TRANSAMINATION OF NITROGEN-CONTAINING COMPOUNDS TO MAKE CYCLIC AND CYCLIC/ACYCLIC POLYAMINE MIXTURES<br/>[FR] TRANSAMINATION DE COMPOSÉS CONTENANT DE L'AZOTE POUR PRÉPARER DES MÉLANGES DE POLYAMINES CYCLIQUES ET CYCLIQUES/ACYCLIQUES
  申请人：DOW GLOBAL TECHNOLOGIES LLC

  公开号：WO2012064483A1

  公开（公告）日：2012-05-18

  A transamination process is described to prepare polyamine product mixtures from reactants comprising mixed nitrogen-containing compounds with binary carbon spacing between nitrogen-containing groups (a binary component). A second nitrogen-containing component with a second carbon atom spacing between nitrogen-containing groups may also be employed. The molar ratio between the binary and second components can be adjusted to customize the product composition for desired end uses.

  描述了一种转氨过程，用于从包含混合氮化合物的反应物制备聚胺产品混合物（一种二元组分），其中氮含基团之间的碳间距是二元的。也可以使用第二个含氮组分，其中氮含基团之间的碳原子间距是第二的。可以调整二元组分与第二组分之间的摩尔比，以定制产品组成，以满足所需的最终用途。
• Substituted azetidinones as anti-inflammatory and antidegenerative agents
  申请人：Merck & Co., Inc.

  公开号：US05591737A1

  公开（公告）日：1997-01-07

  New substituted azetidinones of the general Formula (I) which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described. ##STR1## wherein R.sub.4 is (a) ##STR2## or (b) ##STR3## where R.sub.x is carboxy C.sub.1-6 alkyl, benzyloxycarbonylC.sub.1-3 alkyl, or t-butoxycarbonylC.sub.1-3 alkyl, wherein Q is a covalent bond or ##STR4## wherein R.sub.5 and R.sub.6 are each individually C.sub.1-3 alkyl or hydrogen, Y is ##STR5## or a covalent bond.

  本文描述了一般式（I）的新型取代的氮杂四元环，这些化合物被发现具有很强的弹性蛋白酶抑制作用，因此可用作抗炎和抗变性剂。其中，R.sub.4为（a）##STR2##或（b）##STR3##其中R.sub.x为羧基C.sub.1-6烷基，苄氧羰基C.sub.1-3烷基或叔丁氧羰基C.sub.1-3烷基，Q为共价键或##STR4##其中R.sub.5和R.sub.6各自为C.sub.1-3烷基或氢，Y为##STR5##或共价键。
• Pyrazole derivative
  申请人：Kanaya Naoaki

  公开号：US20060128685A1

  公开（公告）日：2006-06-15

  The present invention is directed to a strong platelet aggregation-inhibiting agent which does not inhibit COX-1 or COX-2. The present invention provides compounds represented by formula (I) or formula (II), salts of the compounds, and solvates of the compounds or the salts. Also provided are medicaments containing any of the compounds, salts, or solvates and preventive and/or therapeutic agents for ischemic diseases, containing any of the compounds, salts, or the solvates.

  本发明旨在提供一种强的血小板聚集抑制剂，其不抑制COX-1或COX-2。本发明提供了由式（I）或式（II）表示的化合物，化合物的盐以及化合物或盐的溶剂。还提供了包含任何一种化合物、盐或溶剂的药物以及预防和/或治疗缺血性疾病的制剂，其中包含任何一种化合物、盐或溶剂。
• Five-membered heterocyclic derivative
  申请人：Okayama Toru

  公开号：US20060189591A1

  公开（公告）日：2006-08-24

  The present invention relates to a compound represented by formula (I): a salt of the compound, or a solvate of the compound or the salt; a drug containing any of the compounds, the salts, and the solvates; a preventive and/or therapeutic agent for an ischemic disease containing any of the compounds, the salts, and the solvates; and a platelet coagulation inhibitor containing any of the compounds, the salts, and the solvates. The compound of the present invention is useful as a strong platelet coagulation inhibitor without inhibiting COX-1 or COX-2.

  本发明涉及一种由公式（I）表示的化合物：该化合物的盐，或该化合物或盐的溶剂化物；含有任何该化合物、盐和溶剂化物的药物；含有任何该化合物、盐和溶剂化物的缺血性疾病的预防和/或治疗剂；以及含有任何该化合物、盐和溶剂化物的血小板凝集抑制剂。本发明的化合物在不抑制COX-1或COX-2的情况下作为强效的血小板凝集抑制剂非常有用。